NASDAQ:XOMA - XOMA Stock Price, Price Target & More

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

XOMA Corp (NASDAQ:XOMA) released its quarterly earnings data on Wednesday, May, 9th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.07. The biotechnology company earned $0.46 million during the quarter, compared to analysts' expectations of $3.69 million. XOMA had a negative return on equity of 670.15% and a net margin of 40.44%. View XOMA's Earnings History.

XOMA is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for XOMA.

3 brokerages have issued 1 year price objectives for XOMA's stock. Their forecasts range from $33.00 to $49.00. On average, they anticipate XOMA's stock price to reach $41.00 in the next year. This suggests a possible upside of 77.3% from the stock's current price. View Analyst Ratings for XOMA.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

XOMA saw a increase in short interest in June. As of June 29th, there was short interest totalling 905,211 shares, an increase of 73.6% from the June 15th total of 521,409 shares. Based on an average daily volume of 214,835 shares, the short-interest ratio is presently 4.2 days. Approximately 11.7% of the shares of the stock are sold short. View XOMA's Current Options Chain.

Some companies that are related to XOMA include Rocket Pharmaceuticals (RCKT), Kiniksa Pharmaceuticals (KNSA), CymaBay Therapeutics (CBAY), Amphastar Pharmaceuticals (AMPH), AMAG Pharmaceuticals (AMAG), Adamas Pharmaceuticals (ADMS), AC Immune (ACIU), Cara Therapeutics (CARA), Aptinyx (APTX), GlycoMimetics (GLYC), Abeona Therapeutics (ABEO), Vectura Group (VEGPF), Urogen Pharma (URGN), Kura Oncology (KURA) and Viking Therapeutics (VKTX).

News headlines about XOMA stock have been trending somewhat negative this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. XOMA earned a daily sentiment score of -0.02 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 45.24 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of XOMA stock can currently be purchased for approximately $23.13.

XOMA has a market capitalization of $193.64 million and generates $52.69 million in revenue each year. The biotechnology company earns $14.59 million in net income (profit) each year or $0.98 on an earnings per share basis. XOMA employs 12 workers across the globe.

XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-204-7239 or via email at [email protected]